ClinicalTrials.gg
RecruitingNCT05022446Updated Aug 10, 2026

The Impact of COVID-19 on Pulmonary Procedures

An observational study in COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
250
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in COVID-19 by M.D. Anderson Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. COVID-19 · M.D. Anderson Cancer Center.

Planned enrollment
8th of 10
250 · median 600
Started
2020
with 10 others
Observational
10 of 14
5 open now
Registered
12th of 14
by date

Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2020, is one of 10 observational ones, and was the 12th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

5 of the 14 studies in COVID-19 by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in COVID-19 by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess how pulmonary medicine programs adapted their procedural practices and techniques, ambulatory operations, and provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.

OUTLINE:

Participants complete survey over 5-10 minutes.

03

Conditions studied

  • COVID-19 Infection
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)
  • These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership

Exclusion criteria

Exclusion Criteria:

None

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)

Groups and cohorts

  • Observational (survey)

    Participants complete survey over 5-10 minutes.

    Other: Survey Administration

Interventions

  • OtherSurvey Administration

    Complete survey

06

What researchers measure

Primary outcomes

  1. To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic.

    Time frame: through study completion, an average of 1 year

  2. To evaluate the pulmonary medicine programs that adapted their provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.

    Time frame: through study completion, an average of 1 year

  3. To evaluate the pulmonary medicine programs that adapted their techniques in response to the coronavirus-2019 (COVID-19) epidemic.

    Time frame: through study completion, an average of 1 year

  4. To evaluate the pulmonary medicine programs that adapted their ambulatory operations in response to the coronavirus-2019 (COVID-19) epidemic.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Feb 2027, 74 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Aug 26, 2021
StartActual
Nov 11, 2020
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05022446
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Nov 11, 2020
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Jhankruti F Zaveri, MPH
Contact
jzaveri@mdanderson.org
(713) 745-2645
Bruce F Sabath, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion